SG11201604503XA - Cytotoxic antibody - Google Patents

Cytotoxic antibody

Info

Publication number
SG11201604503XA
SG11201604503XA SG11201604503XA SG11201604503XA SG11201604503XA SG 11201604503X A SG11201604503X A SG 11201604503XA SG 11201604503X A SG11201604503X A SG 11201604503XA SG 11201604503X A SG11201604503X A SG 11201604503XA SG 11201604503X A SG11201604503X A SG 11201604503XA
Authority
SG
Singapore
Prior art keywords
cytotoxic antibody
cytotoxic
antibody
Prior art date
Application number
SG11201604503XA
Inventor
Boon Hwa Andre Choo
Jiyun Zheng
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG11201604503XA priority Critical patent/SG11201604503XA/en
Publication of SG11201604503XA publication Critical patent/SG11201604503XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • C12N5/163Animal cells one of the fusion partners being a B or a T lymphocyte
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081Purging biological preparations of unwanted cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201604503XA 2013-12-03 2014-12-02 Cytotoxic antibody SG11201604503XA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201604503XA SG11201604503XA (en) 2013-12-03 2014-12-02 Cytotoxic antibody

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2013089644 2013-12-03
PCT/SG2014/000570 WO2015084262A2 (en) 2013-12-03 2014-12-02 Cytotoxic antibody
SG11201604503XA SG11201604503XA (en) 2013-12-03 2014-12-02 Cytotoxic antibody

Publications (1)

Publication Number Publication Date
SG11201604503XA true SG11201604503XA (en) 2016-07-28

Family

ID=53274247

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201604503XA SG11201604503XA (en) 2013-12-03 2014-12-02 Cytotoxic antibody

Country Status (4)

Country Link
US (2) US10428312B2 (en)
JP (1) JP6594875B2 (en)
SG (1) SG11201604503XA (en)
WO (1) WO2015084262A2 (en)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607009A (en) * 1983-09-16 1986-08-19 The Wistar Institute Lewis blood group phenotype assay
CN101252951B (en) * 2005-06-30 2011-12-21 森托科尔公司 Anti-IL-23 antibodies, compositions, methods and uses
JP5507086B2 (en) * 2006-03-06 2014-05-28 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ Method of human embryonic stem cells and expression of PODXL
WO2008087259A1 (en) * 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
ES2543095T3 (en) * 2009-07-10 2015-08-14 Innate Pharma TLR3 binding agents
SG183171A1 (en) * 2010-02-04 2012-09-27 Agency Science Tech & Res Use of novel markers of pluripotent stem cells
US8686152B2 (en) * 2010-03-10 2014-04-01 Janssen Pharmaceutica Nv 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
BR112012028764A2 (en) * 2010-05-11 2017-03-14 Aveo Pharmaceuticals Inc anti-pos antifgfr2
EP2593594B1 (en) * 2010-07-16 2017-09-27 Adimab, LLC Antibody libraries
SG187163A1 (en) * 2010-07-21 2013-02-28 Agency Science Tech & Res Methods for identifying candidate cytotoxic antibody molecules
EP3539985A1 (en) * 2012-02-24 2019-09-18 AbbVie Stemcentrx LLC Anti sez6 antibodies and methods of use
US20150344567A1 (en) * 2012-12-21 2015-12-03 The Ritsumeikan Trust iPS/ES CELL-SPECIFIC ANTIBODY HAVING CYTOTOXICITY TO TARGET CELLS AND USE THEREOF
SG11201608489VA (en) * 2014-04-11 2016-11-29 Agency Science Tech & Res Enrichment and characterization of human corneal endothelial cells (hcenc) with novel monoclonal antibody

Also Published As

Publication number Publication date
JP6594875B2 (en) 2019-10-23
JP2016540509A (en) 2016-12-28
US10428312B2 (en) 2019-10-01
WO2015084262A3 (en) 2015-08-13
US11512292B2 (en) 2022-11-29
US20170002331A1 (en) 2017-01-05
WO2015084262A2 (en) 2015-06-11
US20200140828A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti-fcrh5 antibodies
HUE047194T2 (en) Anti-pdl1 antibody formulations
GB201322583D0 (en) Antibodies
HK1212614A1 (en) Antibody formulations
HK1220142A1 (en) Antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488A0 (en) Anti-ccl17 antibodies
GB201312226D0 (en) Improved antibodies
SG11201604503XA (en) Cytotoxic antibody
GB201318283D0 (en) Antibodies
GB201301845D0 (en) Antibody delivery